Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 24;8(7):1593805. doi: 10.1080/2162402X.2019.1593805

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 6. — Changes in CD3(-)PD-L1+ TEX during therapy. (a): Patients who did not have recurrence had significantly increased levels of these exosomes at baseline relative to patients with recurrence with a significant decrease at week 5. Also, in patients with recurrence, there was a significant increase of CD3(-)PD-L1+ TEX at weeks 5 and 14 relative to baseline. (b): Changes in CD3(-)CTLA4+ TEX during therapy. Note that in patients with recurrence, the baseline levels of these exosomes were significantly lower than those in patients with NED and remained low throughout therapy, whereas in patients with no evident disease decreasing levels of CD3(-)CTLA4+ exosomes are visible during therapy. *p < 0.05, **p < 0.005; NSD: no significant difference for overall comparison of changes from baseline.